GlassScriptPhysician profile
William L Gibson
NPI 1083609606
$1,201.26
in general payments reported to CMS, 2019-2025
25 companies · $68.99 in 2025
The $68.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $175 · 2021: $377 · 2022: $132 · 2023: $238 · 2024: $20.22 · 2025: $68.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $211.77 | 2019-2025 | Haegarda |
| Otsuka America Pharmaceutical, INC. | $115.35 | 2022-2023 | Rexulti |
| Novo Nordisk INC | $111.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $92.93 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $88.63 | 2021-2022 | |
| Abbvie INC. | $78.21 | 2021 | |
| Esperion Therapeutics, INC. | $70.19 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $61.01 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $37.88 | 2025 | Eylea Hd, Eylea |
| Pharming Healthcare, INC. | $34.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.94 | 2021-2022 | |
| Lilly USA, LLC | $29.81 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $26.92 | 2023 | Gemtesa |
| Shire North American Group INC | $24.41 | 2019 | |
| Amarin Pharma, INC. | $21.07 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $20.31 | 2020 | |
| Roche Diagnostics Corporation | $20.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.84 | 2022 | |
| Glaxosmithkline, LLC. | $18.41 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2019 | |
| Dexcom, INC. | $14.48 | 2021 | |
| Neurocrine Biosciences, INC. | $14.48 | 2023 | Ingrezza |
| Allergan, INC. | $14.37 | 2019 | |
| Merck Sharp & Dohme LLC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.